Management of Arthropathy in Moderately Deficient Factor VII Patients: Results From Hospital Developed Treatment Protocol

Benson Babu, Jayprakash Belle, John Preshanth Kumar Pathiraj

Abstract


Background: Factor VII deficiency (FVIId) is a rare inherited bleeding disorder whose prevalence is estimated to be 1 in 300,000 - 500,000 in general population. In India, the epidemiological data on factor VII (FVII) disorder are scarce. Serious arthropathy is observed in cases which are severely affected with spontaneous bleeding and hemarthrosis. In such cases, orthopedic surgery is required. Fresh frozen plasma, prothrombin complex concentrates, factor VII concentrates - plasma derived and recombinant factor VII (rFVII) are different types of preparations which are available as therapeutic options in treatment for bleeding occurring during or after surgery in FVIId patients. The main objective of our study was to give a result of the treatment protocol for FVIId patients undergoing orthopedic surgery in our hospital and compare its results with other studies conducted around the world.

Methods: A retrospective study on patients admitted during 2008 - 2014 was carried out with 10 patients diagnosed with FVIID, of whom six undergone surgery at Kasturba Hospital, Manipal, west coastal region of southern India.

Results: FVII baseline plasma levels were less than 10 IU/dL in our patients. Three patients underwent complete hip replacement, while rest of the three patients underwent various other arthroscopic procedures. rFVII was administered every 8 hours on the surgery day, followed by ever 12 - 24 hours for subsequent days in hospital depending on the type of surgery that the patient underwent. FVII levels in plasma were determined once before and once after the surgery, but the dosing of rFVII was not dependent on it. Dosing of rFVII on the day of surgery was 10 - 25 μg/kg and on following days, it was 15 - 30 μg/kg. The number of dosing on patients ranged from 16 to 31. None of our patients developed serious bleeding episode, thus no blood transfusion was required.

Conclusion: Our study results show that when rFVII is administered according to our treatment regimen, it is effective for patients with arthropathy. It also proves that rFVII is the best hemostatic agent for FVII patients.




J Hematol. 2016;5(3):94-98
doi: http://dx.doi.org/10.14740/jh296e


Keywords


Factor VII; Bleeding; Arthropathy; Recombinant factor VII; Orthopedic; Arthroscopy; Thromboprophylaxis; Hemostasis

Full Text: HTML PDF
 
Home     |     Log In     |      About     |      Search     |      Current     |      Archives     |      Submit      |     Subscribe


 

     

Aims and Scope

Current Issues

Conflict of Interest

About Publisher

Editorial Board

Archives

Copyright

Company Profile

Editorial Office

Misconduct and Retraction

Permissions

Company Registration

Contact Us

Abstracting and Indexing

ICMJE

Ownership

Instructions to Authors

Access

Declaration of Helsinki

Contact Publisher

Submission Checklist

Reprints

Terms of Use

Company Address

Submit a Manuscript

Open Access Policy

Privacy Policy

Browse Journals

Publishing Fee

Publishing Policy

Disclaimer

Recent Highlights

Peer-Review Process

Publishing Quality

Code of Ethics

Advertising Policy

Manuscript Tracking

Advanced Search

For Librarians

Careers

Publishing Process

Publication Frequency

For Reviewers

Propose a New Journal

       
       

Journal of Hematology, quarterly, ISSN 1927-1212 (print), 1927-1220 (online), published by Elmer Press Inc.            
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC BY-NC 4.0)



This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.thejh.org    editorial contact: editor@thejh.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada
 

© Elmer Press Inc. All Rights Reserved.

IMPORTANT: THIS JOURNAL SITE OUTLOOK IS DESIGNED BY THE PUBLISHER AND COPYRIGHT PROTECTED. DO NOT COPY!